What Happens to Vitamin D Levels During Menopause?

What Happens to Vitamin D Levels During Menopause?

Vitamin D levels fall in most women during and after menopause, primarily because estrogen regulates enzymes involved in converting vitamin D to its active form. The main caveat: how much they fall depends on baseline status, sun exposure, and diet. Women who enter perimenopause already deficient — which is most of them, given that roughly 42% of U.S. adults are below 20 ng/mL (Forrest & Stuhldreher, Nutrition Research 2011; PMID: 21310306) — face the sharpest consequences for bone density, mood, and immune function.

---

Why Menopause Lowers Vitamin D Status

Estrogen is not just a reproductive hormone. It actively upregulates the renal enzyme CYP27B1, which converts 25-hydroxyvitamin D (the storage form measured on blood tests) into 1,25-dihydroxyvitamin D (calcitriol), the biologically active form. When estrogen drops during perimenopause and postmenopause, this conversion becomes less efficient — meaning you can have what looks like an adequate 25(OH)D level on paper but still have insufficient calcitriol at the tissue level.

There is also a receptor dimension. Estrogen increases the expression of vitamin D receptors (VDRs) in osteoblasts, immune cells, and skeletal muscle fibers. Fewer circulating VDRs means each unit of calcitriol accomplishes less biological work. A 2013 cross-sectional study of 559 postmenopausal women found that 25(OH)D levels were inversely correlated with FSH — the pituitary hormone that surges as ovarian function declines — independent of age and BMI, suggesting the hormonal shift itself is mechanistically linked to vitamin D metabolism, not just to aging (Liu et al., Menopause 2013; PMID: 23340662).

A third factor is renal calcium handling. Calcitriol instructs the intestine to absorb dietary calcium and the kidneys to reabsorb it rather than excrete it. As calcitriol production falls, calcium absorption in the gut drops — from roughly 38% in premenopausal women to around 20–25% in postmenopausal women who are not supplementing — a change that forces the parathyroid glands to compensate by secreting more PTH, which in turn pulls calcium out of bone (Heaney et al., Journal of Bone and Mineral Research 1989; PMID: 2816496).

Finally, adipose tissue accumulates more vitamin D than it releases. Because menopause is associated with increased visceral fat deposition — even in women whose body weight does not change significantly — a greater fraction of circulating vitamin D becomes sequestered in fat depots, further reducing bioavailability (Earthman et al., Obesity Reviews 2012; PMID: 22212629).

---

What Low Vitamin D in Menopause Actually Does to Your Body

The skeletal effects receive the most attention, but vitamin D deficiency during menopause reaches into multiple systems.

Bone density. The combination of falling estrogen and falling calcitriol creates a double hit on bone remodeling. Osteoclasts (cells that break down bone) become relatively more active than osteoblasts (cells that build bone). The Women's Health Initiative Calcium/Vitamin D trial — 36,282 postmenopausal women, seven years, 400 IU vitamin D3 plus 1,000 mg calcium daily — showed modest but significant hip bone density preservation in the supplemented group, though the dose was now considered subtherapeutic by most endocrinologists (Jackson et al., New England Journal of Medicine 2006; PMID: 16481635). Subsequent analyses have shown that doses of 800–2,000 IU produce larger effects on fracture risk, particularly in women whose baseline 25(OH)D was below 20 ng/mL.

Mood and cognitive function. VDRs are densely expressed in the hippocampus and prefrontal cortex. Calcitriol modulates the synthesis of serotonin by upregulating tryptophan hydroxylase — the rate-limiting enzyme in serotonin production. This may partly explain why many women report worsening mood, brain fog, and even depression symptoms during menopause that respond poorly to standard antidepressant therapy. Observational data consistently show that postmenopausal women with 25(OH)D below 20 ng/mL score significantly lower on cognitive measures than those above 30 ng/mL.

Muscle strength and fall risk. VDRs in skeletal muscle regulate the fast-twitch (type II) fiber contractions most critical for balance and fall prevention. A meta-analysis of 13 randomized trials found that vitamin D supplementation at ≥800 IU daily reduced fall risk by 19% in older adults — an effect size that is clinically meaningful for postmenopausal women who are already losing 1–2% of muscle mass per year (Bischoff-Ferrari et al., BMJ 2009; PMID: 19797342).

Immune dysregulation. Vitamin D is a potent immunomodulator — it dampens excessive Th1 and Th17 responses while promoting regulatory T-cell activity. Menopause is associated with a shift toward a more pro-inflammatory immune environment (often called "inflammaging"), and low vitamin D likely amplifies this shift. For women who notice that autoimmune flares, allergies, or infections become more frequent or severe around perimenopause, suboptimal vitamin D status is a plausible contributing factor worth testing. You can read about how other hormonal shifts interact with immune function in why your menopause symptoms change week to week.

Cardiovascular risk. Calcitriol suppresses renin expression, which helps regulate blood pressure. It also reduces vascular smooth muscle proliferation and inflammatory cytokine expression in arterial walls. Postmenopausal women already face an accelerated rise in cardiovascular risk as estrogen's vasculoprotective effects disappear; adding vitamin D insufficiency compounds that trajectory.

---

Vitamin K2 Benefits: Why D3 Without K2 Is an Incomplete Strategy

One of the most important — and most overlooked — aspects of vitamin D supplementation during menopause is the requirement for adequate vitamin K2 to direct calcium into bone rather than into soft tissue. This is not a minor theoretical concern.

Vitamin D3 raises intestinal calcium absorption substantially. Vitamin K2 (specifically the MK-7 form) activates two calcium-regulatory proteins: osteocalcin, which incorporates calcium into bone matrix, and matrix Gla protein (MGP), which inhibits calcium from depositing in arterial walls and cartilage. Without sufficient K2, the calcium liberated by vitamin D supplementation has no directional signal — some evidence suggests it can accelerate arterial calcification in K2-deficient individuals.

A three-year randomized trial of 244 healthy postmenopausal women found that MK-7 supplementation at 180 mcg/day significantly improved bone mineral density at the femoral neck and lumbar spine, and also improved measures of arterial stiffness — a dual effect consistent with K2's role in both skeletal and vascular tissue (Knapen et al., Osteoporosis International 2013; PMID: 23525894). This is a genuinely important trial for menopausal women: it enrolled a population directly comparable to the menopause context and ran for 36 months, long enough to capture meaningful bone remodeling changes.

The mechanistic logic is elegant: D3 opens the door for calcium absorption; K2 tells that calcium where to go. Running either without the other is a half-measure. For women navigating bone loss and cardiovascular risk simultaneously — which describes most postmenopausal women — the D3+K2 combination is substantially more rational than D3 alone.

---

Vitamin K2 Dosage: What the Evidence Actually Supports

The K2 dosage question has a reasonably clear answer for the MK-7 form, which is the pharmacokinetically superior isoform because it has a half-life of approximately 72 hours (versus 1–2 hours for MK-4), allowing once-daily dosing to maintain consistent plasma levels.

The Knapen 2013 trial cited above used 180 mcg/day of MK-7 — currently the most-cited dose in bone health literature for postmenopausal women. A 2019 systematic review confirmed that 90–180 mcg/day MK-7 is the effective range for osteocalcin carboxylation (the biochemical marker of K2 activity in bone), with 180 mcg producing near-complete carboxylation in most subjects.

For vitamin D3, the clinical consensus has shifted considerably since the WHI trial's 400 IU arm. Current guidance from the Endocrine Society for adults with frank deficiency is 1,500–2,000 IU/day for maintenance, with loading doses of 50,000 IU weekly (physician-supervised) to correct deficiency faster. For postmenopausal women with baseline levels in the 20–30 ng/mL range, 1,000–2,000 IU daily of D3 is a reasonable target — but individual response varies enough that retesting at 3 months is the only reliable way to know if a dose is working. Always work with a healthcare provider before significantly changing your vitamin D dose, particularly if you have kidney disease or a history of hypercalcemia.

For context on what appropriate vitamin D dosing looks like clinically — including the range where toxicity becomes a concern — the clinical guide to vitamin D3 dosage and overdose covers that in detail.

---

Vitamin K2 Overdose Symptoms: What You Should Know

Unlike fat-soluble vitamins A and D, vitamin K2 (MK-7) has a very favorable safety profile at typical supplemental doses. There is no established Tolerable Upper Intake Level (UL) for K2 in healthy adults, and true toxicity from dietary or supplemental K2 is not documented in the literature.

The primary safety consideration is pharmacological rather than toxicological: vitamin K2 can reduce the effectiveness of warfarin (coumadin) and other vitamin K antagonist anticoagulants. Patients on these medications should not add K2 supplementation without close INR monitoring and physician guidance.

At doses used in research (90–360 mcg/day of MK-7), no adverse effects have been observed in controlled trials. Theoretical concern about hypercalcemia is occasionally raised in the context of D3+K2 supplementation, but the research evidence actually suggests the opposite — that adequate K2 reduces risk of soft-tissue calcium deposition, not increases it. If you are taking both D3 and calcium carbonate supplements in large amounts and also have reduced kidney function, that combination warrants medical supervision regardless of K2 status.

If you notice symptoms like unexplained bruising, bleeding changes, or GI upset while starting a K2 supplement, discontinue and consult a healthcare provider — though these are more likely related to other factors than to K2 itself.

---

Testing: What Levels to Aim For

The standard test is serum 25-hydroxyvitamin D [25(OH)D]. Laboratories and guidelines differ slightly on reference ranges, but most endocrinologists now use:

For postmenopausal women specifically, many functional medicine practitioners and endocrinologists target the 40–60 ng/mL range for bone and immune benefits, though evidence for outcomes above 50 ng/mL is thinner. Testing at baseline and 3 months post-supplementation is the minimum; annual testing thereafter is reasonable for most people.

It is also worth noting that 25(OH)D alone does not capture the CYP27B1 conversion issue described earlier. Parathyroid hormone (PTH) is a useful companion marker — elevated PTH in the setting of seemingly adequate 25(OH)D suggests that calcitriol production is not keeping up, which can happen even when the storage form looks normal.

For a broader look at hormone testing during menopause — including FSH, which correlates with vitamin D metabolism — the article on what happens to FSH levels during menopause covers the relationship between pituitary signaling and the broader hormonal transition.

Women interested in whether other nutritional deficiencies compound these hormonal changes — particularly B vitamins, which also decline during menopause — can find a detailed breakdown in do B vitamins help with menopause symptoms.

---

What This Means for Your Formula

Ones includes Vitamin D3 + K2 (MK-7) as a paired combination, dosed at clinically relevant levels — D3 at ranges calibrated to baseline blood work and K2 as MK-7 at 180 mcg, matching the dose used in the Knapen 2013 postmenopausal bone trial. Rather than defaulting everyone to the same 1,000 IU of D3, the Ones AI reviews your 25(OH)D level from lab results and adjusts the D3 dose accordingly — a meaningful difference for women who are frankly deficient versus those who are borderline insufficient.

For postmenopausal women with concurrent inflammation, the formula may also include Omega-3 (EPA+DHA), which synergizes with vitamin D's immunomodulatory effects by further suppressing NF-κB signaling and IL-6 production — a combination that addresses both the hormonal and inflammatory dimensions of the menopausal transition. And for women whose lab work or symptom picture suggests adrenal stress is compounding their hormonal shift, Ones' Adrenal Support blend may be included in the formula — because cortisol dysregulation and estrogen decline often interact in ways that a single-ingredient approach cannot address.

If you are curious how other aspects of menopause are supported without hormone therapy, what helps with menopause symptoms without hormones covers the evidence for several non-hormonal approaches, including several ingredients that work alongside vitamin D.

---

Key Takeaways

• Estrogen loss during menopause reduces the efficiency of vitamin D activation in the kidneys (via CYP27B1 downregulation) and reduces vitamin D receptor expression in bone, muscle, and immune tissue — so women can be functionally deficient even with blood levels that appear normal.
• The consequences include accelerated bone loss, increased fracture risk, mood and cognitive changes, muscle weakness, immune dysregulation, and elevated cardiovascular risk — not just osteoporosis.
• Vitamin K2 (MK-7 at 180 mcg/day) is a necessary partner to D3 supplementation: it activates osteocalcin and MGP to direct calcium into bone and out of arterial walls.
• K2 has no established upper intake limit and does not cause toxicity at supplemental doses, but it interacts with warfarin and other vitamin K antagonists — medical supervision is required if you are anticoagulated.
• Target 25(OH)D of 40–60 ng/mL for postmenopausal women; retest at 3 months to confirm your dose is working; check PTH as a companion marker.
• A personalized approach — starting from your actual lab values rather than a standard dose — produces meaningfully better outcomes, since individual response to vitamin D supplementation varies by two to three fold across adults.